Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Nathan Fowler, MD
M.D. Anderson Cancer Center
Study Chair - Susan O'Brien, MD
University of California Irvine Cancer Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tg Therapeutics Investigational Trial Site
Huntsville, Alabama, United States
- Tg Therapeutics Investigational Trial Site
Jonesboro, Arkansas, United States
- Tg Therapeutics Investigational Trial Site
Duarte, California, United States
- Tg Therapeutics Investigational Trial Site
Atlanta, Georgia, United States
- Tg Therapeutics Investigational Trial Site
Omaha, Nebraska, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Dec 2013
- Primary completion
- 31 Oct 2019
- Completion
- 31 Oct 2019
- Last update posted
- 5 Nov 2019
- Registered enrollment
- 160
- Registry id
- NCT02006485
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.